Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
News & Media
Home
>
News & Media
>
Media
Media
Media
Filter by Year:
2023
2022
2021
2-Jul-2021
Peak TV interview 2 July 2021
12-Jan-2021
Neuren Pharmaceuticals receives EC Orphan designations for drug candidate NNZ-2591
19-Nov-2020
Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial
4-Mar-2020
Neuren Pharmaceuticals secures Rare Pediatric Disease designation for trofinetide to treat Rett Syndrome
5-Dec-2017
Neuren Pharmaceuticals gets green light for a patent in the U.S.
29-Jun-2017
Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials
22-Mar-2017
Neuren Pharmaceuticals drug shows promise in treating Rett syndrome
19-Mar-2017
Neuren Pharmaceuticals granted ASX trading halt pending trial update
25-Aug-2016
Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome
27-Jun-2016
Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome
Previous
1
2
3
Next
